Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 33.3%Low 2 · 66.7%Moderate 0 · 0%High 0 · 0%

Postoperative MMC‐EMDA induction vs MMC‐PD induction therapy

Time to recurrence

Postoperative MMC‐EMDA induction may leads to lower time to recurrence compared with MMC‐PD induction therapy (low certainty).

1 finding from 1 review

Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
RR 0.65 [0.44, 0.98]
1 study · 72 participants
Low

Postoperative MMC‐EMDA induction vs postoperative BCG induction therapy

Time to recurrence

It is very uncertain whether postoperative MMC‐EMDA induction changes time to recurrence compared with postoperative BCG induction therapy (very low certainty).

1 finding from 1 review

Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
RR 1.06 [0.64, 1.76]
1 study · 72 participants
Very low

Postoperative MMC‐EMDA with sequential BCG induction and maintenance vs postoperative BCG induction and maintenance therapy

Time to recurrence

Postoperative MMC‐EMDA with sequential BCG induction and maintenance may leads to lower time to recurrence compared with postoperative BCG induction and maintenance therapy (low certainty).

1 finding from 1 review

Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
HR 0.51 [0.34, 0.77]
1 study · 212 participants
Low